Log in
Enquire now
‌

US Patent 11191757 Combination of pimavanserin and cytochrome P450 modulators

Patent 11191757 was granted and assigned to Acadia Pharmaceuticals on December, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Acadia Pharmaceuticals
Acadia Pharmaceuticals
0
Date Filed
November 15, 2019
0
Date of Patent
December 7, 2021
0
Patent Applicant
Acadia Pharmaceuticals
Acadia Pharmaceuticals
0
Patent Application Number
16684883
0
Patent Citations Received
‌
US Patent 11840515 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
0
‌
US Patent 11464768 Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
Patent Inventor Names
Andrew Parkinson
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11191757
0
Patent Primary Examiner
‌
Sarah Pihonak
0

Find more entities like US Patent 11191757 Combination of pimavanserin and cytochrome P450 modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.